Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.

Arzneimittel-Forschung

Volumn 60, Issue 6 a, 2010, Pages 373-385

  Geisser, Peter ^a   Rumyantsev, Vitaly ^b  

^a Vifor (International) Inc   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; FERRIC CARBOXYMALTOSE; FERRIC ION; FERRITIN; HEMOGLOBIN; MALTOSE; TRANSFERRIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IRON DEFICIENCY ANEMIA; MALE; METABOLISM; MIDDLE AGED; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADOLESCENT; ADULT; ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRIC COMPOUNDS; FERRITINS; GASTROINTESTINAL DISEASES; HEMOGLOBINS; HUMANS; MALE; MALTOSE; MIDDLE AGED; PATIENT SELECTION; TRANSFERRIN;

EID: 77956802593     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296302     Document Type: Article

References (0)